Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
36,000
+1,150 (3.30%)
Sep 19, 2025, 3:30 PM KST
3.30%
Market Cap758.49B
Revenue (ttm)20.88B
Net Income (ttm)-8.83B
Shares Out21.07M
EPS (ttm)-675.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume217,320
Average Volume207,700
Open35,000
Previous Close34,850
Day's Range34,750 - 36,500
52-Week Range15,950 - 42,250
Betan/a
RSI80.40
Earnings DateNov 14, 2025

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company focuses on degrader-antibody conjugate that combine antibody-drug conjugate with targeted protein degradation technology. Its lead product candidate is ORM-1153, a GSPT1 protein degrader that targets hematologic malignancies. The company was founded in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 21
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.